Syros Historical Balance Sheet

SYRS Stock

USD 0.27 0.02 8.00%

Trend analysis of Syros Pharmaceuticals balance sheet accounts such as Other Liabilities of 29.5 M, Net Tangible Assets of 179.4 M, Property Plant And Equipment Net of 16.6 M or Accounts Payable of 12.1 M provides information on Syros Pharmaceuticals' total assets, liabilities, and equity, which is the actual value of Syros Pharmaceuticals to its prevalent stockholders. By breaking down trends over time using Syros Pharmaceuticals balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining Syros Pharmaceuticals latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Syros Pharmaceuticals is a good buy for the upcoming year.

Syros Pharmaceuticals Inventory

1.09

Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Syros Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For more information on how to buy Syros Stock please use our How to Invest in Syros Pharmaceuticals guide.

About Syros Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Syros Pharmaceuticals at a specified time, usually calculated after every quarter, six months, or one year. Syros Pharmaceuticals Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Syros Pharmaceuticals and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Syros currently owns. An asset can also be divided into two categories, current and non-current.

Syros Pharmaceuticals Balance Sheet Chart

At this time, Syros Pharmaceuticals' Accumulated Other Comprehensive Income is comparatively stable compared to the past year. Short Term Debt is likely to gain to about 11.9 M in 2024, whereas Other Current Liabilities is likely to drop slightly above 10.7 M in 2024.

Total Assets Other Current Liab Total Current Liabilities Total Stockholder Equity Long Term Debt Current Deferred Revenue

Add Fundamental

Total Assets

Total assets refers to the total amount of Syros Pharmaceuticals assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Syros Pharmaceuticals books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Current Liabilities

Total Current Liabilities is an item on Syros Pharmaceuticals balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Syros Pharmaceuticals are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Total Stockholder Equity

The total equity held by shareholders, calculated as the difference between a company's total assets and total liabilities. It represents the net value of the company owned by shareholders.

Long Term Debt

Long-term debt is a debt that Syros Pharmaceuticals has held for over one year. Long-term debt appears on Syros Pharmaceuticals balance sheet and also includes long-term leases. The most common forms of long term debt are bonds payable, long-term notes payable, mortgage payable, pension liabilities, and lease liabilities. In the corporate world, long-term debt is generally used to fund big-ticket items, such as machinery, buildings, and land. The total of long-term debt reported on Syros Pharmaceuticals balance sheet is the sum of the balances of all categories of long-term debt. Debt that is not due within the current year and is often considered to be financing activities that are to be repaid over several years.

Current Deferred Revenue

Revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends.

Most accounts from Syros Pharmaceuticals' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Syros Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Syros Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For more information on how to buy Syros Stock please use our How to Invest in Syros Pharmaceuticals guide.At this time, Syros Pharmaceuticals' Accumulated Other Comprehensive Income is comparatively stable compared to the past year. Short Term Debt is likely to gain to about 11.9 M in 2024, whereas Other Current Liabilities is likely to drop slightly above 10.7 M in 2024.

	2021	2022	2023	2024 (projected)
Other Current Liabilities	13.6M	15.9M	13.8M	10.7M
Total Assets	182.9M	244.5M	168.2M	147.5M

Other Current Liab Total Assets

Syros Pharmaceuticals balance sheet Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Long Term Debt	Cash And Short Term Investments	Net Receivables	Common Stock Total Equity	Common Stock Shares Outstanding	Short Term Investments	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Deferred Long Term Liab	Property Plant And Equipment Gross
Total Assets		0.81	0.91	0.44	0.81	0.85	0.9	-0.47	-0.83	0.56	0.84	0.89	0.75	0.81	0.88	0.97	0.03	0.69	0.55	-0.16	0.85	0.88	0.92	0.86	0.18	0.94
Other Current Liab	0.81		0.92	0.28	0.66	0.88	0.71	-0.12	-0.82	0.64	0.49	0.73	0.74	0.52	0.86	0.78	0.43	0.72	0.58	0.12	0.69	0.81	0.9	0.74	-0.25	0.76
Total Current Liabilities	0.91	0.92		0.18	0.8	0.9	0.87	-0.24	-0.91	0.72	0.68	0.87	0.8	0.74	0.91	0.86	0.19	0.72	0.66	-0.14	0.86	0.86	0.98	0.89	0.06	0.91
Total Stockholder Equity	0.44	0.28	0.18		-0.01	0.1	0.31	-0.13	0.08	-0.41	0.28	0.33	0.21	0.2	0.35	0.45	0.2	0.28	-0.43	0.53	-0.08	0.28	0.21	-0.06	0.07	0.33
Other Liab	0.81	0.66	0.8	-0.01		0.83	0.78	-0.53	-0.85	0.81	0.73	0.68	0.44	0.77	0.75	0.79	0.07	0.72	0.76	-0.43	0.91	0.74	0.79	0.91	0.09	0.75
Net Tangible Assets	0.85	0.88	0.9	0.1	0.83		0.73	-0.39	-0.93	0.77	0.66	0.72	0.66	0.65	0.76	0.85	0.15	0.74	0.79	-0.28	0.88	0.8	0.9	0.9	-0.2	0.77
Property Plant And Equipment Net	0.9	0.71	0.87	0.31	0.78	0.73		-0.16	-0.75	0.56	0.63	0.97	0.64	0.76	0.86	0.78	0.14	0.73	0.45	-0.09	0.8	0.73	0.83	0.81	0.36	0.97
Net Debt	-0.47	-0.12	-0.24	-0.13	-0.53	-0.39	-0.16		0.39	-0.26	-0.82	-0.11	-0.19	-0.59	-0.2	-0.62	0.52	-0.16	-0.41	0.67	-0.51	-0.41	-0.33	-0.46	-0.08	-0.21
Retained Earnings	-0.83	-0.82	-0.91	0.08	-0.85	-0.93	-0.75	0.39		-0.89	-0.7	-0.75	-0.76	-0.65	-0.76	-0.81	0.01	-0.55	-0.9	0.37	-0.96	-0.86	-0.92	-0.97	-0.01	-0.82
Accounts Payable	0.56	0.64	0.72	-0.41	0.81	0.77	0.56	-0.26	-0.89		0.45	0.52	0.56	0.45	0.54	0.52	-0.01	0.41	0.94	-0.44	0.85	0.7	0.71	0.86	0.01	0.6
Cash	0.84	0.49	0.68	0.28	0.73	0.66	0.63	-0.82	-0.7	0.45		0.62	0.6	0.86	0.61	0.9	-0.38	0.42	0.53	-0.54	0.79	0.75	0.74	0.77	0.3	0.7
Non Current Assets Total	0.89	0.73	0.87	0.33	0.68	0.72	0.97	-0.11	-0.75	0.52	0.62		0.76	0.71	0.85	0.78	0.08	0.65	0.44	-0.04	0.78	0.74	0.83	0.8	0.36	0.98
Non Currrent Assets Other	0.75	0.74	0.8	0.21	0.44	0.66	0.64	-0.19	-0.76	0.56	0.6	0.76		0.51	0.64	0.72	-0.14	0.27	0.53	-0.08	0.68	0.81	0.81	0.71	0.23	0.78
Other Assets	0.81	0.52	0.74	0.2	0.77	0.65	0.76	-0.59	-0.65	0.45	0.86	0.71	0.51		0.67	0.81	-0.12	0.7	0.42	-0.51	0.77	0.58	0.71	0.77	0.3	0.73
Long Term Debt	0.88	0.86	0.91	0.35	0.75	0.76	0.86	-0.2	-0.76	0.54	0.61	0.85	0.64	0.67		0.82	0.31	0.74	0.47	0.07	0.74	0.76	0.88	0.77	0.03	0.86
Cash And Short Term Investments	0.97	0.78	0.86	0.45	0.79	0.85	0.78	-0.62	-0.81	0.52	0.9	0.78	0.72	0.81	0.82		-0.04	0.64	0.56	-0.24	0.82	0.87	0.9	0.83	0.09	0.84
Net Receivables	0.03	0.43	0.19	0.2	0.07	0.15	0.14	0.52	0.01	-0.01	-0.38	0.08	-0.14	-0.12	0.31	-0.04		0.51	-0.13	0.66	-0.14	-0.01	0.14	-0.07	-0.55	0.05
Common Stock Total Equity	0.69	0.72	0.72	0.28	0.72	0.74	0.73	-0.16	-0.55	0.41	0.42	0.65	0.27	0.7	0.74	0.64	0.51		0.31	-0.04	0.58	0.42	0.63	0.61	-0.22	0.62
Common Stock Shares Outstanding	0.55	0.58	0.66	-0.43	0.76	0.79	0.45	-0.41	-0.9	0.94	0.53	0.44	0.53	0.42	0.47	0.56	-0.13	0.31		-0.55	0.86	0.68	0.7	0.86	-0.09	0.53
Short Term Investments	-0.16	0.12	-0.14	0.53	-0.43	-0.28	-0.09	0.67	0.37	-0.44	-0.54	-0.04	-0.08	-0.51	0.07	-0.24	0.66	-0.04	-0.55		-0.53	-0.11	-0.15	-0.47	-0.23	-0.09
Non Current Liabilities Total	0.85	0.69	0.86	-0.08	0.91	0.88	0.8	-0.51	-0.96	0.85	0.79	0.78	0.68	0.77	0.74	0.82	-0.14	0.58	0.86	-0.53		0.8	0.87	1.0	0.16	0.83
Other Current Assets	0.88	0.81	0.86	0.28	0.74	0.8	0.73	-0.41	-0.86	0.7	0.75	0.74	0.81	0.58	0.76	0.87	-0.01	0.42	0.68	-0.11	0.8		0.93	0.81	0.18	0.85
Other Stockholder Equity	0.92	0.9	0.98	0.21	0.79	0.9	0.83	-0.33	-0.92	0.71	0.74	0.83	0.81	0.71	0.88	0.9	0.14	0.63	0.7	-0.15	0.87	0.93		0.89	0.07	0.9
Total Liab	0.86	0.74	0.89	-0.06	0.91	0.9	0.81	-0.46	-0.97	0.86	0.77	0.8	0.71	0.77	0.77	0.83	-0.07	0.61	0.86	-0.47	1.0	0.81	0.89		0.12	0.85
Deferred Long Term Liab	0.18	-0.25	0.06	0.07	0.09	-0.2	0.36	-0.08	-0.01	0.01	0.3	0.36	0.23	0.3	0.03	0.09	-0.55	-0.22	-0.09	-0.23	0.16	0.18	0.07	0.12		0.36
Property Plant And Equipment Gross	0.94	0.76	0.91	0.33	0.75	0.77	0.97	-0.21	-0.82	0.6	0.7	0.98	0.78	0.73	0.86	0.84	0.05	0.62	0.53	-0.09	0.83	0.85	0.9	0.85	0.36

Click cells to compare fundamentals

Syros Pharmaceuticals Account Relationship Matchups

Syros Pharmaceuticals balance sheet Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	150.0M	213.3M	182.9M	244.5M	168.2M	147.5M
Other Current Liab	10.6M	9.4M	13.6M	15.9M	13.8M	10.7M
Total Current Liabilities	23.5M	28.6M	31.5M	30.8M	36.7M	22.2M
Total Stockholder Equity	79.2M	90.6M	85.2M	127.7M	16.7M	15.8M
Other Liab	22.6M	29.6M	3.0M	24.5M	28.1M	29.5M
Net Tangible Assets	79.2M	125.4M	106.1M	148.6M	170.9M	179.4M
Property Plant And Equipment Net	31.9M	29.6M	27.3M	24.7M	19.5M	16.6M
Net Debt	(15.5M)	(107.8M)	(27.1M)	(103.9M)	(77.5M)	(81.3M)
Retained Earnings	(293.0M)	(377.0M)	(463.6M)	(558.2M)	(722.8M)	(686.7M)
Accounts Payable	5.9M	3.6M	3.7M	6.4M	11.5M	12.1M
Cash	41.4M	174.0M	92.3M	167.5M	139.5M	93.7M
Non Current Assets Total	35.5M	34.7M	46.4M	33.1M	23.2M	21.7M
Non Currrent Assets Other	490K	2.0M	6.0M	5.3M	3.7M	2.6M
Other Assets	3.6M	20.5M	6.0M	8.4M	9.7M	5.4M
Cash And Short Term Investments	91.4M	174.0M	130.4M	202.3M	139.5M	119.8M
Common Stock Total Equity	26K	34K	43K	56K	20K	28.2K
Common Stock Shares Outstanding	4.0M	4.6M	6.3M	12.6M	28.3M	29.7M
Short Term Investments	39.8M	49.8M	50.0M	0.0	38.1M	34.8M
Liabilities And Stockholders Equity	150.0M	213.3M	182.9M	244.5M	168.2M	147.5M
Non Current Liabilities Total	47.3M	94.1M	66.2M	86.0M	114.8M	120.6M
Other Current Assets	2.6M	2.2M	3.2M	7.4M	5.5M	2.8M
Other Stockholder Equity	372.1M	467.5M	548.8M	685.8M	739.4M	377.3M
Total Liab	70.8M	122.7M	97.7M	116.8M	151.5M	159.1M
Property Plant And Equipment Gross	31.9M	29.6M	37.1M	37.2M	27.1M	19.9M
Total Current Assets	114.5M	178.6M	136.6M	211.4M	145.0M	125.8M
Accumulated Other Comprehensive Income	24K	0.0	(79K)	102K	117.3K	123.2K
Short Term Debt	1.3M	3.5M	4.0M	4.1M	11.3M	11.9M
Common Stock	34K	43K	56K	61K	20K	32.1K
Property Plant Equipment	31.9M	14.2M	27.3M	11.4M	13.1M	12.6M
Short Long Term Debt Total	25.9M	66.2M	65.2M	63.6M	62.1M	34.7M
Long Term Debt Total	22K	621K	39.6M	40.6M	46.7M	49.1M
Capital Surpluse	296.1M	372.1M	467.5M	685.8M	788.7M	828.2M
Current Deferred Revenue	5.7M	12.2M	10.2M	4.3M	5.0M	6.4M
Retained Earnings Total Equity	(217.5M)	(293.0M)	(377.0M)	(558.2M)	(502.4M)	(477.3M)
Capital Lease Obligations	25.9M	26.7M	24.9M	22.9M	20.9M	16.7M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Syros Stock Analysis

When running Syros Pharmaceuticals' price analysis, check to measure Syros Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Syros Pharmaceuticals is operating at the current time. Most of Syros Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Syros Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Syros Pharmaceuticals' price. Additionally, you may evaluate how the addition of Syros Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Syros Historical Balance Sheet

Syros Pharmaceuticals Inventory

1.09

About Syros Balance Sheet Analysis

Syros Pharmaceuticals Balance Sheet Chart

Total Assets

Total Current Liabilities

Total Stockholder Equity

Long Term Debt

Current Deferred Revenue

Syros Pharmaceuticals balance sheet Correlations

Syros Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Syros Pharmaceuticals balance sheet Accounts

Thematic Opportunities

Explore Investment Opportunities

Additional Tools for Syros Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Liab	+ 1.0	Non Current Liabilities Total
Other Stockholder Equity	+ 0.98	Total Current Liabilities
Property Plant And Equipment Gross	+ 0.98	Non Current Assets Total
Cash And Short Term Investments	+ 0.97	Total Assets
Non Current Assets Total	+ 0.97	Property Plant And Equipment Net
Property Plant And Equipment Gross	+ 0.97	Property Plant And Equipment Net

Total Liab	- 0.97	Retained Earnings
Non Current Liabilities Total	- 0.96	Retained Earnings
Retained Earnings	- 0.93	Net Tangible Assets
Other Stockholder Equity	- 0.92	Retained Earnings
Retained Earnings	- 0.91	Total Current Liabilities
Common Stock Shares Outstanding	- 0.9	Retained Earnings